This article is from the source 'bbc' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.bbc.co.uk/news/world-asia-india-63146262

The article has changed 4 times. There is an RSS feed of changes available.

Version 1 Version 2
Maiden Pharmaceuticals: WHO links Gambia deaths to India-made cough syrups Maiden Pharmaceuticals: India investigates cough syrups after Gambia deaths
(1 day later)
The WHO has advised regulators to stop the sale of the four cough syrupsThe WHO has advised regulators to stop the sale of the four cough syrups
The World Health Organization has issued a product alert on four cough syrups made in India, linking them with 66 child deaths in The Gambia. The Indian government has ordered an investigation into four cough syrups after the World Health Organization (WHO) linked them to the deaths of 66 children in The Gambia.
This came after an investigation into the deaths of children from kidney injuries in the West African country. The WHO said the children had died of kidney injuries. It said it found "unacceptable" levels of toxins in the syrups made by Maiden Pharmaceuticals.
The health body is "conducting further investigation" with the firm - Maiden Pharmaceuticals - and Indian authorities. It also advised regulators to stop sale of the products.
It has also advised regulators to stop sale of the syrups. Maiden Pharmaceuticals has not yet commented.
India's health ministry and drugs regulator are yet to officially comment on the WHO's product alert, which it published on its website. The BBC has contacted the company for comment.
The BBC has emailed Maiden Pharmaceuticals for comment. India's national drug regulator began investigating after the WHO contacted it on 29 September, an Indian government statement said.
Indian government sources told the BBC on condition of anonymity that India's drug regulator had launched an investigation after it was informed of the issue on 29 September. The regulator has also asked the WHO to share its report establishing the "causal relation to death with the medical products in question", the statement added.
The regulator has also asked the WHO to share its report establishing the "causal relation to death with the medical products in question", they said.
The WHO findings, announced by Director-General Tedros Adhanom Ghebreyesus on Wednesday, came after samples of each of the four cough syrups were tested. It identified the medicines as Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup.The WHO findings, announced by Director-General Tedros Adhanom Ghebreyesus on Wednesday, came after samples of each of the four cough syrups were tested. It identified the medicines as Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup.
The health body said that laboratory analysis had confirmed that the syrups contain "unacceptable amounts" of diethylene glycol and ethylene glycol, which are toxic to humans and can prove fatal when consumed. The health body said that laboratory analysis had confirmed that the syrups contained unacceptable amounts of diethylene glycol and ethylene glycol, which were toxic to humans and could prove fatal when consumed.
The WHO said that so far, the products have been identified in The Gambia, but that they may have been distributed to other countries through informal markets.The WHO said that so far, the products have been identified in The Gambia, but that they may have been distributed to other countries through informal markets.
The Indian government, however, said it had exported these cough syrups "only to The Gambia so far".
The health body said it was "conducting further investigation" with the firm and Indian authorities.
"All batches of these products should be considered unsafe until they can be analysed by the relevant National Regulatory Authorities," it added."All batches of these products should be considered unsafe until they can be analysed by the relevant National Regulatory Authorities," it added.
However, the sources cited above said that the company has exported these cough syrups "only to The Gambia so far".
India produces a third of the world's medicines, mostly in the form of generic drugs.India produces a third of the world's medicines, mostly in the form of generic drugs.
Home to some of the fastest growing pharmaceutical companies, the country is known as the "world's pharmacy" and meets much of the medical needs of African nations.Home to some of the fastest growing pharmaceutical companies, the country is known as the "world's pharmacy" and meets much of the medical needs of African nations.
Maiden Pharmaceuticals, which is based in the northern state of Haryana, exports its products to countries in Asia, Africa and Latin America, according to Reuters.Maiden Pharmaceuticals, which is based in the northern state of Haryana, exports its products to countries in Asia, Africa and Latin America, according to Reuters.
Medical officers in The Gambia first raised the alarm in July after dozens of children were diagnosed with serious kidney problems.Medical officers in The Gambia first raised the alarm in July after dozens of children were diagnosed with serious kidney problems.
The Gambia's director of health services, Mustapha Bittaye, told Reuters that the number of deaths had gone down in recent weeks and that the country had banned the sale of the products.The Gambia's director of health services, Mustapha Bittaye, told Reuters that the number of deaths had gone down in recent weeks and that the country had banned the sale of the products.
"However, until recently, some of the syrups were still being sold in private clinics and in hospitals," he was quoted as saying."However, until recently, some of the syrups were still being sold in private clinics and in hospitals," he was quoted as saying.
Read more India stories from the BBC:Read more India stories from the BBC:
Can India be China’s ‘plus one’ to the world?Can India be China’s ‘plus one’ to the world?
Calls grow to drop Bollywood director from India show
The Indian period drama firing up the box officeThe Indian period drama firing up the box office
The problem of 'dirty money' in Indian politicsThe problem of 'dirty money' in Indian politics
Why India's abortion ruling is a huge step forwardWhy India's abortion ruling is a huge step forward
An Indian maharaja and a 'mystery' willAn Indian maharaja and a 'mystery' will
Moonlighting debate divides Indian firms and workers